Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Endocrinology
•
Bone and Calcium Disorders
Is there a target alkaline phosphatase level for hypophosphatasia patients on asfotase alfa therapy?
Answer from: at Academic Institution
The package insert states, “do not rely on serum alkaline phosphatase measurements for clinical decision making in patients treated with Strensiq”.
Sign In
or
Register
to read more
29136
Related Questions
What are some practical tips in distinguishing between metabolic bone disease due to chronic kidney disease and osteoporosis?
Is there an evidence-based consensus on CT-derived Hounsfield unit thresholds for opportunistic assessment of osteoporosis, and how should such measurements be applied when DXA results are inconclusive or do not meet diagnostic criteria?
Do you recommend initiating zoledronic acid for osteoporosis at the time of hospitalization for a fracture?
How do you counsel patients on the risks and benefits of strontium supplements for osteoporosis management?
What patient factors are most important when considering who needs a broader workup for osteoporosis prior to starting therapy?
Do you use bone turnover markers to assess medical adherence in patients treated for osteoporosis?
When stopping denosumab and transitioning to PO bisphosphonate, do you wait for 6 months after the last denosumab injection to start PO bisphosphonate?
Are SGLT2 inhibitors contraindicated in patients with osteoporosis and history of vertebral and hip fractures?
Is Evenity appropriate for a patient with severe osteoporosis (T-score -3.1) unresponsive to bisphosphonates and persistent primary hyperparathyroidism despite two surgeries?
In a patient with severe osteoporosis (T-score -3.9) and multiple vertebral fractures in the setting of multiple myeloma with bone involvement, would you consider adding an anabolic agent such as romosozumab or teriparatide despite concerns about osteosarcoma risk?